CRISPR Therapeutics AG reports developments in gene-based medicines built around CRISPR/Cas9 gene editing, cell therapy, in vivo editing and siRNA programs. Recurring updates cover CASGEVY, developed with Vertex for severe sickle cell disease and transfusion-dependent beta thalassemia, as well as pipeline work in cardiovascular disease, autoimmune disease, oncology, rare disease and Type 1 diabetes.
Company news also includes financial results, business updates, investor conference presentations, manufacturing and platform disclosures, collaborations such as Sirius Therapeutics, and capital actions involving common shares or convertible senior notes.
CRISPR Therapeutics (CRSP) will present Phase 1 zugo-cel data in refractory systemic sclerosis at ACR Convergence on November 8, 2026. The poster, titled “Safety and Efficacy of Anti-CD19 Allogeneic Chimeric Antigen Receptor (CAR) T Cell Therapy Zugocabtagene Geleucel (zugo-cel) in Patients with Refractory Systemic Sclerosis,” is scheduled for 10:30 a.m. ET in Poster Session A, abstract 0225.
Zugo-cel is an investigational, gene-edited immune-cell therapy targeting CD19. It is being evaluated in Phase 1 trials across rheumatologic, hematologic and neurologic autoimmune indications. The presentation will be available at crisprtx.com after it concludes.
CRISPR Therapeutics (CRSP)/b) announced that senior management will present at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026, at 1:05 p.m. EST.A live webcast of the fireside chat will be available on the Investors "Events & Presentations" page of the company website, with a replay accessible for 14 days after the presentation.
CRISPR Therapeutics (Nasdaq: CRSP) reported updated Phase 1a data for CTX310, its in vivo CRISPR/Cas9 therapy targeting ANGPTL3, at ESC Congress 2026 and in The New England Journal of Medicine. A single IV dose produced deep, dose-dependent and durable lipid lowering sustained through one year in 15 participants.
At the highest 0.8 mg/kg dose, mean reductions from baseline were 79% for ANGPTL3 (maximum 89%), 48% for triglycerides (maximum 78%) and 53% for LDL (maximum 84%). CTX310 was generally well tolerated, with no treatment-related serious adverse events, no ≥Grade 3 liver enzyme changes and no new treatment-related safety events on extended follow-up. The company has begun a Phase 1b trial using a flat dose equivalent to 0.8 mg/kg and expects a further CTX310 update, focused on severe hypertriglyceridemia patients, in the second half of 2026.
Agomab Therapeutics (Nasdaq: AGMB) announced that its Board has proposed appointing Marino Garcia and Naimish Patel, M.D. as non-executive directors, subject to shareholder approval at a Special General Meeting on September 11, 2026 in Antwerp, Belgium. Garcia is President, CEO and director of Dianthus Therapeutics (Nasdaq: DNTH), while Dr. Patel is Chief Medical Officer of CRISPR Therapeutics (Nasdaq: CRSP).
Agomab will also hold an Extraordinary General Shareholders’ Meeting the same day at 2:30 PM CEST to seek approval for a proposed consolidation and split of outstanding pre-IPO warrants, adjusting each warrant to reflect the share split implemented with Agomab’s February 2026 IPO. Meeting materials and detailed biographies are available on Agomab’s investor website.
CRISPR Therapeutics (Nasdaq: CRSP) reported second quarter 2026 CASGEVY® revenue of $76 million, up 78% quarter-over-quarter and 151% year-over-year, and highlighted expanded approval, including recent U.S. FDA authorization for children aged ≥2 years with SCD or TDT.
The company advanced multiple programs, initiating Phase 1 trials for CTX340 in refractory hypertension, CTX460 for AATD, and additional zugo-cel autoimmune neurologic and oncology studies, while CTX310 and CTX611 progressed in cardiovascular and thromboembolic indications.
Cash, cash equivalents and marketable securities were $2,364.4 million as of June 30, 2026, supported by $585.4 million in net proceeds from convertible senior notes. R&D expense was $67.2 million, G&A $17.6 million, collaboration expense $40.3 million, and net loss narrowed to $91.2 million from $208.5 million a year earlier.
CRISPR Therapeutics (Nasdaq: CRSP) announced participation by senior management in three June 2026 investor conferences: Jefferies Global Healthcare Conference, William Blair’s 46th Annual Growth Stock Conference, and Goldman Sachs’ 47th Annual Global Healthcare Conference.
Live webcasts and 14-day replays will be available on the company’s investor website.
CRISPR Therapeutics (Nasdaq: CRSP) announced its senior management will present at the Bank of America Securities 2026 Global Healthcare Conference on Tuesday, May 12, 2026 at 1:40 p.m. PDT. A live webcast will be available on the company's Investors "Events & Presentations" page, with a replay archived for 14 days.
CRISPR Therapeutics (Nasdaq: CRSP) reported Q1 2026 results and business progress on May 4, 2026. Key metrics: CASGEVY revenue $43.0M, >500 patients initiated, $2.44B cash (Mar 31, 2026) following $585.4M convertible notes issuance. Multiple in vivo IND/CTA advances, IND clearance for CTX310 U.S. expansion, clinical starts expected mid‑2026 for CTX460 and CTX340, and ongoing zugo‑cel trials across autoimmune and oncology indications.
R&D, G&A, and collaboration expenses moderated vs. prior year; net loss was $122.9M for Q1 2026. Several clinical and commercial milestones are expected in H2 2026.
CRISPR Therapeutics (Nasdaq: CRSP) will present at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026 at 2:15 p.m. ET. A live webcast of the fireside chat will be available on the company’s Investors "Events & Presentations" page. A replay will be archived for 14 days.
CRISPR Therapeutics (Nasdaq: CRSP) priced an upsized private offering of $550 million aggregate principal amount of 2031 convertible senior notes, plus a $50 million initial purchaser option. Closing is expected on March 16, 2026.
The notes bear an effective coupon increased to 1.7308% to offset anticipated Swiss withholding, mature on March 1, 2031, and convert at 13.0617 shares per $1,000 (initial conversion price ~$76.56, ~45% premium to the March 10, 2026 share price). Estimated net proceeds are ~$536.3 million (or ~$585.2 million if option exercised).